COMMUNIQUÉS West-GlobeNewswire

Enara Bio’s DARKFOX Discovery Propels ENA101, the First Ever Bispecific T Cell Engager Targeting a Cancer-Specific Dark Antigen, into IND-Enabling Studies
04/11/2025
Enara’s discovery of DARKFOX delivers on the vision of translating the dark genome into a new class of clinically actionable Dark Antigens and will be highlighted in an oral presentation at SITC 2025 DARKFOX [...]
Trading by management and close relations of management
04/11/2025
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of [...]
Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
04/11/2025
CT-P72/ABP-102 poster selected as one of the Top 150 abstracts out of more than 1,300 submissions at SITC 2025 CT-P72/ABP-102 demonstrates potent and selective anti-tumor activity in HER2-high models, including Enhertu- [...]
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
04/11/2025
- CX-801 (PROBODY ® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma - - Data supportive of CX-801’s mechanism of action and the ongoing [...]
LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform
04/11/2025
Transaction Values WorkSimpli at $65 Million Enterprise Value; Supports LifeMD’s Strategic Focus on Scaling its Virtual Care and Pharmacy Businesses NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD [...]
Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available
04/11/2025
Data to be presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting on November 7th and 9th BOSTON and LONDON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology [...]
Novo Nordisk submits updated proposal to acquire Metsera, Inc.
04/11/2025
Bagsværd, Denmark, 4 November 2025 – On 30 October 2025, Novo Nordisk announced the submission of an unsolicited proposal to acquire Metsera, Inc. (Metsera) 1 . Today, Novo Nordisk confirms that it has submitted an [...]
H.H.C. Group Achieves ISO/IEC 27001:2022 Certification, Strengthening Commitment to Data Security and Client Trust
04/11/2025
ROCKVILLE, Md., Nov. 04, 2025 (GLOBE NEWSWIRE) -- H.H.C. Group (H.H.C.), a leader in reducing healthcare costs by providing high-quality cost containment using claim negotiation, repricing and independent review [...]
Baylor Genetics to Highlight Genetic Testing Use Cases and Advancements in Rare Disease at The National Society of Genetic Counselors 44th Annual Conference
04/11/2025
HOUSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics , a clinical diagnostic laboratory at the forefront of genetic testing, will exhibit its latest scientific research and findings in genetic testing at The [...]
Humber River Health to Open James B. Neill Simulation Centre, Strengthening Ontario’s Healthcare Workforce and Advancing Innovative Patient Care
04/11/2025
TORONTO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- As Ontario’s healthcare system faces unprecedented strain, Humber River Health is taking decisive action to help build a stronger, future-ready workforce with the launch of the [...]
Lyric Health and Curaechoice Partner to Deliver $0-Cost Virtual Health Care Access Nationwide
04/11/2025
Birmingham, Alabama, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lyric Health , the award-winning telehealth service provider ranked #1 in the U.S. among all virtual care providers, has announced a strategic partnership with [...]
Lungpacer Medical Announces First Enrollments in STARI Trial of Next-Generation Neurostimulation Therapy
04/11/2025
STARI will investigate continual diaphragm neurostimulation to improve lung, diaphragm, cardiac and brain function at the earliest stages of mechanical ventilation EXTON, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lungpacer [...]
Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control
04/11/2025
-- Advances 5x30 strategy by expanding pipeline with a highly complementary asset that has the potential to provide several days of pain control -- -- Phase 2 program for AMT-143 expected to begin in 2026 -- BRISBANE, [...]
Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
04/11/2025
Initial results of a Phase 1 / 2 open label study of AT-02, the company’s lead pan-amyloid removal therapeutic candidate, in patients with AL amyloidosis will be presented at ASH. The presentation includes data on AL [...]
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
04/11/2025
SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA submission [...]
Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)
04/11/2025
MELBOURNE, Australia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent [...]
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection
04/11/2025
Planning to initiate an open-label Phase 2 study of TNX-1500 under an investigator-initiated IND to evaluate safety and activity in the first half of 2026 Novel immunomodulatory regimen designed to reduce calcineurin [...]
Secura Bio Announces Poster Presentation Highlighting Extended Follow Up Analyses from Phase 2 PRIMO Trial at the 2025 American Society of Hematology Meeting
04/11/2025
BERKELEY HEIGHTS, N. J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( www.securabio.com ), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced a poster [...]
Purespring to present three posters at the American Society of Nephrology Kidney Week 2025
04/11/2025
New information to be presented on the study design and methodology of Purespring’s Phase I/II trial of PS-002, an AAV-based therapy delivering the complement factor I to podocytes in patients with IgA nephropathy [...]

Pages